65,437 trials
Asthma
Primary: Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #3 — 2.68; 1.63 score on a scale — p=0.385
Coronary Stenosis · Coronary Artery Stenosis · In-stent Restenosis
Primary: Number of Device Procedural Success(Lesions Level) — 68; 68 lesions
Rib Fractures
Primary: Acute Pain Assessed by Numeric Pain Score — 5.61; 5.93 score on a scale — p=0.493
Knee Arthroplasty
Primary: Objectively Measured (Actigraph) Sedentary Behavior at 2 Months — 659.52; 638.24 minutes/day
Coronary Heart Disease
Primary: Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model — 0.7191; 0.5478; 0.4512; 0.3901 ratio serum levels of IL-6 — p=0.0011
Diabetes Mellitus, Type 2
Primary: Percent of All Glucose Values Within Glucose Range < 70 mg/dL — 0 Percentage of all glucose values
Non Alcoholic Steatohepatitis · Fibrosis
Primary: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 — 9; 4 Participants
Rosacea
Primary: Adherence - MEMs Cap — 21; 6; 15; 12 Participants
White Spot Lesion
Primary: White Spot Measurement — 34; 37; 1; 0 Lesions
Bariatric Surgery
Primary: Number of Intervention Sessions Completed — 9.6 Sessions completed
Insomnia
Primary: Continuous Performance Test (CPT) — 56.2; 55.8 T-Score
Gastrointestinal Bleeding
Primary: Re-bleeding — 6; 7 Participants
Infertility, Male
Primary: Sperm Progressive Motility — 19.62; 25.11 percentage
Total Knee Arthroplasty · Opioid Use
Primary: Cumulative Opioid Consumption 24-48 Hours Post-operatively — 8; 15 morphine milligram equivalents — p=0.27
Cancer
Primary: Feasibility of a Pre-simulation VR Platform Prior to Radiation — 25 Participants